Clinical Trial Update: A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation [Phase 1]

View source ↗

Summary

Phase 1 study investigating siltuximab for antibody-mediated rejection after lung transplantation is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection After Lung Transplantation

Drugs mentioned

• Sylvant (siltuximab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Antibody Mediated Rejection of Lung Transplant | Phase 1 | Status: RECRUITING